Gritstone bio Inc (CE) (GRTSQ) 시세

GRTS changed to GRTSQ, bankruptcy. Delisted from the Nasdaq to the OTC: ***pps dropped 41% from .047 to .0278 on 58 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

IMMENSE DUMPING

DELISTING DUMPING

THIS STOCK GETS DELISTED OR SPLIT...NO WAY OUT...B ECAREFUL WITH NASDAQ BIOS UNDER A DOLLAR...OR ANY FOR THAT MATTER.......HOWEVER WACH TOMORROW...IS THERE ANOTHER VTEK COMING...JUST MAYBE.... STAY TUNED!!!
SOMEONE ASKED ME ABOUT THIS STOCK, ONLY REASON TO POST.

What price was the offering?

UNREPENTANT DUMPING

CONTINUOUS SELLING

.0789 + 40%

GRTS.............................https://stockcharts.com/h-sc/ui?s=GRTS&p=W&b=5&g=0&id=p86431144783

BANKRUPTCY DUMPING

bankrupt

https://stockcharts.com/h-sc/ui RSI is at 22

Funny part 16 million buys to 12 million sells 2 million neutral.

UNBELIEVABLE DUMPING

Including neoantigens for recognition by CD4+ T-cells greatly improved the effectiveness, while tumour-unrelated CD4+ T-cell antigens did not https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(24)00077-8

Still the only company I'm aware of that is able to induce such a rapid, robust and consistent large number of CD8+ T-cells.



But having a strong CD8+ T-cell response is useless without the right selection https://www.science.org/doi/10.1126/scitranslmed.aax7918

EDGE does not specifically model immunogenicity but performs reasonably well at predicting immunogenic peptides (immunogenicity is >50% of mutations per patient generate a detectable CD8+ T-cell response).

CD4+ T-cell responses are important as well (but prediction is a lot harder) https://www.nature.com/articles/s41586-019-1671-8

Also, what setting it is given is equally important. They (vaccines in general) likely offer a greater benefit to the patient if administered in earlier clinical settings, such as the adjuvant setting, for a number of reasons.

GRTS new 52 lo

And then the offering....classic bs

GRTS—(-40%/AH)—reports purportedly-positive interim phase-2 data:

https://www.globenewswire.com/news-release/2024/04/01/2855416/0/en/Gritstone-bio-Announces-Positive-Preliminary-Progression-free-Survival-and-Long-term-Circulating-Tumor-DNA-ctDNA-Data-from-Phase-2-Portion-of-Ongoing-Phase-2-3-Study-of-its-Persona.html Gritstone bio…today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC).

Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Emphasis added.

The results could be difficult to interpret as Gritstone is primarily evaluating ctDNA, an endpoint that doesn't have the full backing from any regulator that I know of. Gritstone could also report other data, but the company argues that radiographic endpoints aren't as good as ctDNA, which means that the endpoints might not match up.

Yep, looking past $3 now…let’s ride!!!😎🍻🍻✌️

grts breaking 2.75 trigger

GRTS...NEXT STOP 2.75

GRTS MONSTER CANCER PLAY

GRTS WHAT A MONSTER...LETS SEE 2.46 NEXT

GRTS....READY FOR 2.32

That’s next…

GRTS...I THINK THEY CURED CANCER

GRTS READY FOR 2.37

Merry Christmas $$$

GRTS under $2

Wow, finally some company. LOL!!! Oncology side is even stronger. Barda $$$ was great though. LFG!!!

Gritstone Bio shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7. >>>>> GRTS

I wonder how many people know that this is a cornovavirus stock company… hmmm

Sounds like you're keeping a close eye on this one. Hoping for the best!

This is just the appetizer. Shorties going to get roasted once float locks up. Lots of shares sold at these levels. Longs or quick flippers should be rewarded soon

GRTS..BREAKING NICELY

Merry Christmas $$$

They are trying for that cup and handle. Let's goo

Getting up for the next leg. Get in or get left behind.

All IMO of course. Trading well, should be trading much better with a $400 mil grant. I suspect some manipulation to take all the shares they can get.

GRTS ANOTHER BIO READY

Share price holding in AH . Let's see how she runs tomorrow.

Maybe government grants don't count in totaling yearly revenues ! > $$$$$

WE ARE LIKE

underpaid news reporters

https://finviz.com/quote.ashx?t=GRTS&p=d

Barely anyone is selling, and the shorts disappeared…..



Wow, looks good for tomorrow


Have a great night

Latest News

UPDATE 1-Gritstone bio wins $433
million US contract for COVID vaccine study
Sep 27, 2023 at 4:48 p.m. ET
(Adds share price and study details in paragraphs 3-5)
Sept 27 (Reuters) - Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.
The contract is a part of "Project NextGen," an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.
Gritstone's shares rose 36.1% to $1.61 after the bell.
The study will compare the efficacy, safety and immunogenicity of Gritstone's COVID-19 vaccine candidate with an approved vaccine.
Gritstone plans to initiate the mid-stage study in the first quarter of next year.
The contract was awarded by the Biomedical Advanced Research and Development Authority, a U.S. federal agency that funds disease-fighting technology.

WOOHOOOOOO WOOHOOOOOO

Looks like that’s going to change

Horrible Revenues > According to MarketWatch, GRTS annual revenue averages $11,000. per employee.

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.